XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborations (Details)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 1 Months Ended 10 Months Ended 1 Months Ended 1 Months Ended 10 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 10 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended
Sep. 30, 2012
USD ($)
Sep. 30, 2011
USD ($)
Sep. 30, 2012
USD ($)
Sep. 30, 2011
USD ($)
Sep. 30, 2012
Erbitux [Member]
USD ($)
Sep. 30, 2011
Erbitux [Member]
USD ($)
Sep. 30, 2012
Erbitux [Member]
USD ($)
Sep. 30, 2011
Erbitux [Member]
USD ($)
Aug. 31, 2012
Amylin [Member]
USD ($)
Sep. 30, 2012
Amylin [Member]
USD ($)
Sep. 30, 2011
Amylin [Member]
USD ($)
Sep. 30, 2012
Amylin [Member]
USD ($)
Sep. 30, 2011
Amylin [Member]
USD ($)
Sep. 30, 2012
Exenatide [Member]
USD ($)
Sep. 30, 2011
Exenatide [Member]
USD ($)
Sep. 30, 2012
Exenatide [Member]
USD ($)
Sep. 30, 2011
Exenatide [Member]
USD ($)
Mar. 31, 2011
Boerhringer Ingelheim (BI) [Member]
USD ($)
Nov. 30, 2011
Sales NEW [Member]
Amylin [Member]
Oct. 31, 2011
Sales NEW [Member]
Exenatide [Member]
Aug. 31, 2012
Revenue Share [Member]
Amylin [Member]
USD ($)
Nov. 30, 2011
Revenue Share [Member]
Amylin [Member]
USD ($)
Sep. 30, 2012
Revenue Share [Member]
Exenatide Once Weekly [Member]
USD ($)
Nov. 30, 2011
Secured Note [Member]
Amylin [Member]
USD ($)
Nov. 30, 2011
Secured Note, Interest Rate [Member]
Amylin [Member]
Oct. 31, 2011
Gross Margin Share [Member]
Exenatide [Member]
Sep. 30, 2010
Profit and Development and Marketing Share [Member]
Effient [Member]
Mar. 31, 2010
Selling and Marketing Expense [Member]
Necitumumab [Member]
Mar. 31, 2010
Prepaid Selling and Marketing Expense [Member]
Duloxetine BI [Member]
USD ($)
Dec. 31, 2009
Research and Development Exp [Member]
Baricitinib [Member]
Mar. 31, 2010
Research and Development Exp [Member]
United States [Member]
Necitumumab [Member]
Mar. 31, 2010
Research and Development Exp [Member]
Outside the United States [Member]
Necitumumab [Member]
Oct. 31, 2011
Research and Development and Marketing and Selling Expense [Member]
Exenatide [Member]
Mar. 31, 2010
Milestone Payments, Development and Regulatory [Member]
Necitumumab [Member]
USD ($)
Nov. 30, 2011
Milestone Payments, Development and Regulatory [Member]
Amylin [Member]
USD ($)
Mar. 31, 2011
Milestone Payments, Development and Regulatory [Member]
BI compounds [Member]
EUR (€)
Sep. 30, 2011
Milestone Payments, Development and Regulatory [Member]
BI compounds [Member]
USD ($)
Mar. 31, 2011
Milestone Payments, Development and Regulatory [Member]
LLY compounds [Member]
USD ($)
Mar. 31, 2011
Milestone Payments, Development and Regulatory [Member]
LLY optional compound [Member]
USD ($)
Dec. 31, 2009
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
Dec. 31, 2012
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
Dec. 31, 2010
Milestone Payments, Development and Regulatory [Member]
Baricitinib [Member]
USD ($)
Sep. 30, 2011
Milestone Payments, Sales-based [Member]
TPG-Axon [Member]
USD ($)
Dec. 31, 2009
Milestone Payments, Sales-based [Member]
Baricitinib [Member]
USD ($)
Dec. 31, 2009
Royalty [Member]
Baricitinib [Member]
Jun. 30, 2012
Loan Commitment [Member]
Exenatide Once Weekly [Member]
USD ($)
Nov. 30, 2011
Upfront Payment [Member]
Amylin [Member]
USD ($)
Mar. 31, 2010
Profit Share [Member]
Necitumumab [Member]
Nov. 30, 2011
Termination Payments [Member]
United States [Member]
Amylin [Member]
Nov. 30, 2011
Termination Payments [Member]
Outside the United States [Member]
Amylin [Member]
Net product sales $ 5,301.2 $ 5,971.7 $ 16,170.5 $ 17,748.1 $ 6.2 $ 16.2 $ 69.0 $ 61.2           $ 49.5 $ 46.4 $ 151.1 $ 131.9                                                                  
Collaboration and other revenue 142.1 176.2 475.5 491.8 80.4 81.1 241.0 240.1           4.7 60.3 70.1 180.5                                                                  
Revenue 5,443.3 6,147.9 16,646.0 18,239.9 86.6 97.3 310.0 301.3           54.2 106.7 221.2 312.4                                                                  
Research and development 1,342.8 1,280.9 3,815.0 3,665.5                                                                                            
Collaborative Arrangement, Income Statement Classification and Amounts 65.2 58.6 211.0 155.5                                                                                            
Collaborative Arrangement, Rights and Obligations                                         1,260.0 1,200.0   1,200.0         400.0         250.0 150.0 300.0 478.7 650.0 525.0 515.0 50.0 49.0 70.0 150.0   165.0 250.0      
Collaborative Arrangement, Rights and Obligations Percent                                     15.00% 100.00%         9.50% 50.00% 50.00% 50.00%   30.00% 45.00% 72.50% 50.00%                       20.00%     45.00% 65.00% 35.00%
Proceeds from prepayment of revenue-sharing obligation     1,212.1 0         1,210.0                                                                                  
Deferred Revenue, Current                                             490                                                      
Acquired in-process research and development 0 0 0 388.0                           388.0                                                                
Other Nonoperating Income (Expense) $ 22.0 $ (60.6) $ (5.5) $ (71.8)           $ 787.8 $ 0 $ 787.8 $ 0